Abstract
The inhibition of angiogenesis represents a potential strategy for antitumor therapy. A novel synthetic fusion protein VTF, composed of bioactive fragments from two different angiogenesis inhibitors, vasostatin and tumstatin with a (Gly-Ser-Gly)2 bridge, was generated using the pET-15b expression vector. The fusion protein VTF showed significantly enhanced efficacy in inhibiting human endothelial cell proliferation and tube formation and neovascularization on chick embryo chorioallantoic membrane. Moreover, VTF suppressed the growth of B16 melanoma and the formation of tumor blood vessels potently in vivo. These results indicated that the fusion protein containing the bioactive fragments of multiple angiogenesis inhibitors might be a promising therapeutic agent for tumor treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
